Case-control studies evaluating a screening test's efficacy in reducing cancer mortality require accurate classification of test indication to obtain a valid result. However, for analogous studies of cancer incidence, determination of test indication is not as critical because, to define exposure, we need consider only tests that can identify precursor lesions whose treatment might prevent cancer, not tests leading to cancer diagnosis. This study utilizes US Surveillance, Epidemiology, and End Results (SEER)-Medicare data, which do not include information about colonoscopy indication, to evaluate the efficacy of colonoscopy in preventing colorectal cancer (CRC) incidence. Cases were Medicare enrollees diagnosed with CRC between 1996 and 2013; up to 3 controls were matched to each case. Colonoscopy receipt prior to presumed onset of occult cancer was associated with an approximately 60% reduction in CRC incidence (odds ratio = 0.41, 95% confidence interval: 0.40, 0.42). The association was robust to differing exposure windows and estimates of occult cancer duration and is similar to those from CRC incidence studies in which exam indication was available. Our results suggest that, when it is impractical/impossible to determine whether tests were conducted for screening, the efficacy of a test in preventing cancer incidence can still be estimated using a case-control study design. cancer screening; case-control studies; colorectal cancer; incidence Abbreviations: CRC, colorectal cancer; OIP, occult invasive phase; PIDP, preinvasive detectable phase; SEER, Surveillance, Epidemiology, and End Results.
Case-control studies are often used to evaluate the efficacy of cancer screening tests. To obtain unbiased estimates of a screening test's efficacy for reducing cancer mortality, it is necessary to accurately distinguish screening from diagnostic exams (i.e., classify test indication). For example, colonoscopy is used not only to screen for colorectal cancer (CRC) in asymptomatic individuals but also for follow-up evaluation of those in whom there is a suspicion of the presence of CRC (i.e., abnormal results from a fecal immunochemical test or flexible sigmoidoscopy) and to evaluate those with CRC symptoms. If diagnostic exams that identify the presence of CRC are incorrectly classified as "screening," and cases are considered "exposed" on this basis, falsely high estimates of the odds ratio associated with colonoscopy exposure would result (1) (2) (3) .
In contrast, case-control studies that evaluate the efficacy of screening for preventing cancer incidence are less susceptible to the effects of indication misclassification, due to differences in the relevant time periods prior to cancer diagnosis that are examined for exposure. A central tenet of case-control studies of screening efficacy is that exposure history should be ascertained only during the time period in which screening could prevent the outcome of interest (4) . Again using the example of colonoscopy screening, cancer incidence can be prevented only if a precancerous lesion (e.g., colorectal adenoma or sessile serrated polyp) is detected and removed, while cancer mortality can be prevented by either the removal of precancerous lesions (which prevents cancer death by preventing the cancer from ever developing) or by the detection of asymptomatic CRC at a stage when treatment is likely to be successful. The 2 time periods during which precancerous lesions and cancer are present have been referred to as the preinvasive detectable phase (PIDP) and occult invasive phase (OIP), respectively (4) . Therefore, valid case-control studies of cancer mortality should tabulate all screening tests during the combined duration of the PIDP and OIP, while case-control studies of cancer incidence should consider only screening history during the PIDP (Figure 1 ) (4).
There are 2 major reasons that case-control studies examining the efficacy of screening in preventing cancer incidence are less susceptible to bias than those with a cancer mortality endpoint. First, because incidence studies do not consider a colonoscopy that led to cancer diagnosis (given that such a colonoscopy by definition occurs during the OIP), errors in the ascertainment of the reason for that colonoscopy (screening versus diagnosis) will not be relevant. Determining the indication for colonoscopies occurring during the PIDP is not as critical. Because these colonoscopies did not diagnose CRC, they offer an opportunity for cancer prevention via polyp detection and removal regardless of the reason for the exam.
A second, and related, reason for reduced susceptibility to bias has to do with the distributions of the timing of colonoscopies in cases and controls. Even if misclassification of indication were not an issue, in order for a mortality study to provide a valid estimate of efficacy, a disproportionate number of cases will have been screened near the time of diagnosis (i.e., essentially all of those whose cancer was detected by screening, given that colonoscopy is about 95% sensitive for the detection of CRC) (5) . Therefore, if the combined duration of the PIDP and OIP was underestimated, screening utilization would be underestimated to a greater degree among controls than among cases, resulting in an underestimate in the benefit of screening (6) . This clustering of exams near the time of diagnosis means that, in a mortality study, assessment of screening must occur during a calendar time and in age groups where screening is at steady state (7) . During the PIDP, however, a more uniform distribution of screening would be expected in both persons who do and do not go on to develop colorectal cancer, so this potential bias would not be as strong in an incidence study as in a study of screening to prevent cancer mortality.
The determination of test indication in the context of cancer screening can be a laborious, resource-intensive process, and it requires that relevant information is correctly and consistently captured in medical records. However, because test indication is not critical in case-control studies of cancer incidence, administrative claims data ought to be able to provide valid estimates of screening efficacy for those tests with the ability to prevent cancer incidence. In this work, we highlight an example of a case-control study that utilizes Surveillance, Epidemiology, and End Results (SEER)-Medicare data to evaluate the efficacy of colonoscopy in preventing CRC incidence. We additionally examine the sensitivity of the odds ratios to different estimates of PIDP and OIP durations.
METHODS

Data sources
The SEER-Medicare database links data from the 17 population-based SEER cancer registries to Medicare claims data (8) . The combined SEER registries cover approximately 28% of the United States population (9) , and Medicare provides health insurance to the vast majority of US adults over 65 years of age. Data were first linked in 1991 and currently include cancer cases diagnosed through 2013. For each calendar year, a 5% sample of Medicare beneficiaries living in SEER areas and without any SEER record of a cancer diagnosis is also selected for inclusion in the database. For SEER cancer cases diagnosed before 2003, all Medicare claims starting in calendar year 1991 are available. After that time, claims are available for 5-7 years prior to diagnosis, depending on diagnosis year (10) .
Case identification and control selection
For each year between 1996 and 2013, we identified all incident cases of colorectal adenocarcinoma that represented an individual's first malignant diagnosis in SEER (i.e., sequence number 0 or 1), among men and women aged 70-85 years. Age 70 years and calendar year 1996 were chosen as lower limits to allow for identification of all colonoscopies occurring during a minimum of 5 years prior to CRC diagnosis. Cases were further restricted to those individuals who were continuously enrolled in both fee-for-service Medicare Part A (hospital) and Part B (physician/outpatient) for at least 5 years prior to CRC diagnosis and who were never enrolled in a managed care organization during the same time period. Controls were selected from among individuals in the 5% noncancer sample who were alive on the case's diagnosis date (reference date) and who were enrolled in Medicare Part A/B (and not enrolled in managed care) for at least as long as their matched case prior to the reference date.
International Classification of Diseases, Ninth Revision, Current Procedural Terminology, and Healthcare Common Procedure Coding System codes (reported in Web Table 1 , available at https://academic.oup.com/aje) were used to identify additional exclusions, CRC tests, and study covariates. Cases and controls were excluded if they had evidence (from Medicare claims) of CRC or inflammatory bowel disease more than 6 months prior to the reference date or a colonic resection at any time prior to reference date. We also excluded those cases and controls who underwent a barium enema or computed tomography colonography during the estimated PIDP. Controls were matched to each case, without replacement, on the basis of sex, calendar year of birth, race (white, black, other/ unknown), and SEER registry area. When available, 3 controls were randomly selected from eligible controls. If only 1 or 2 potential controls were available, we selected as many as possible; if no controls were available for a case, we dropped that case from analysis. Individual matching ensured that a case and his/her matched controls could have identical time windows for colonoscopy history ascertainment, such that they had essentially identical opportunities to be screened.
Ascertainment of exposures and covariates
The occurrence and dates of colonoscopies were identified using claims from the SEER-Medicare Provider Analysis and Review (MedPAR) files (hospital), outpatient, and carrier files. Prior studies have found Medicare claims to be a highly valid source of information regarding the performance of colonoscopy (11) . Covariates included demographics (age, sex, race, ethnicity, and SEER registry area based on residence at the reference date) from the Patient Entitlement and Diagnosis Summary File (PEDSF) and Summarized Denominator (SUMDENOM) files, ecological-level socioeconomic status measured by median income according to zip code of residence using SEER census files, rural/urban residence based on RuralUrban Continuum coding from the SUMDENOM file, and an adaptation of the Charlson Comorbidity Index developed for use with SEER-Medicare data (12) , based on individual comorbid conditions. For comorbidities, each individual condition was defined using a yes/no variable based on International Classification of Diseases, Ninth Revision, diagnosis codes identified in the hospital, outpatient, and carrier files in the 12 months prior to the reference date, and a weighted sum of the conditions was used to create a composite score. We also considered family history of colorectal cancer (noted at least 6 months prior to reference date, and based on International Classification of Diseases, Ninth Revision, code V16.0) as a potentially confounding variable. However, we ultimately did not include this variable in our models, because we believed it to be inaccurate based on a higher prevalence among controls (3.5%) than among cases (2.0%).
Analysis
Our primary analyses assumed an OIP of either 1 or 2 years in duration, and we considered the PIDP to encompass all available lookback time prior to the estimated onset of the OIP in cases (and the equivalent period in matched controls). We also conducted sensitivity analyses restricting to those case-control sets with at least 10 years of claims available prior to the reference date; this restriction allowed for the examination of the impact of varying the duration of the PIDP in addition to the OIP. In addition to considering OIP durations of 1 or 2 years, the sensitivity analyses examined PIDP durations of either 5 years or all available years prior to the OIP onset. Exposure status was assigned according to whether at least 1 colonoscopy had been performed during the estimated PIDP. Conditional logistic regression models were used to estimate odds ratios and their associated 95% confidence intervals for the association between colonoscopy and the risk of CRC. All models were adjusted for urban/rural residence status (large metropolitan, metropolitan, urban, less urban, or rural), area-level median income (in $: <40,000, 40,000-49,999, 50,000-59,999, 60,000-79,999, ≥80,000, or missing/unknown), and Charlson comorbidity score (0, 1, or ≥2) . Further, all models excluded cases and controls who had had a sigmoidoscopy but no colonoscopy during the lookback window of interest, so that the reference group would be composed of individuals who had had no lower endoscopy during the relevant time period.
RESULTS
Based on inclusion and exclusion criteria, 89,645 cases were eligible for the study. An additional 12,554 cases were excluded due to the inability to identify any matched control(s), leaving 77,091 cases available for analyses ( Figure 2 ). Only 2 matching controls could be identified for 17,477 cases, and only 1 matching control could be identified for 18,845 cases; a total of 176,106 controls were included in the analysis. The median number of months of claims data available before diagnosis/ reference date was 85, with a minimum of 60 and a maximum of 143.
For the primary analysis using a 1-year estimate of the OIP duration, 15% of cases and 29% of controls had at least 1 Medicare claim for colonoscopy during the estimated PIDP, corresponding to an approximately 60% reduction in CRC incidence (odds ratio = 0.41, 95% confidence interval: 0.40, 0.42). For the analysis using a 2-year estimate of the OIP, there were slight decreases in the proportions exposed (13% of cases and 25% of controls), but the relative incidence reduction was similar (odds ratio = 0.45, 95% confidence interval: 0.44, 0.46) ( Table 1) .
In sensitivity analyses restricting to case-control sets in which at least 10 years of Medicare claims data prior to the reference date were available, adjusted odds ratios were similar to those from the primary analysis (ranging from 0.48 to 0.52), regardless of the estimated durations of the OIP (equal to 1 or 2 years) and PIDP (equal to 5 years or all available time prior to OIP onset) used (Table 2) . Again, while the proportion exposed was somewhat lower when shorter exposure windows were used, the relative incidence reduction remained similar. For all analyses, unadjusted models yielded nearly identical odds ratios (data not shown).
DISCUSSION
Regardless of the estimated durations of the OIP and PIDP used in both the primary and sensitivity analyses, our results suggest that individuals receiving colonoscopy were 50%-60% less likely to be diagnosed with CRC than were those with no lower endoscopy. These results are similar to those of other observational studies of CRC incidence in which information regarding colonoscopy indication was available. In a prior case-control study, investigators assessed screening in relation to advanced (stage IIB or higher) CRC as of the time of diagnosis; in that study, conducted in 4 integrated healthcare systems in the United States, the odds ratio associated with receipt of screening colonoscopy within 3 months to 10 years prior to the reference date was 0.29 (95% confidence interval: 0.15, 0.58) (13) . Another analysis conducted within the Nurses' Health Study and Health Professionals Follow-up Study cohorts reported reductions in CRC incidence ranging from 40% to 56% (depending on screening colonoscopy findings) (14) . While the similarity of our results to those of other observational studies does not necessarily indicate the validity of our odds-ratio estimates, it is nonetheless reassuring that our approach, which does not require a labor-intensive ascertainment of exam indication, yielded comparable estimates of the reduction of CRC incidence associated with colonoscopy use.
There are several methodological advantages to studying a cancer incidence outcome rather than a mortality outcome when conducting case-control studies of the efficacy of cancer screening for tests with the ability to prevent both cancer incidence Tables 1 and 2 ). CRC, colorectal cancer; CT, computed tomography; HMO, Health Maintenance Organization; IBD, inflammatory bowel disease. Abbreviations: CI, confidence interval; OR, odds ratio. a Adjusted for urban/rural status (large metropolitan, metropolitan, urban, less urban, rural, unknown), area-level median income (in $: <40,000, 40,000-49,999, 50,000-59,999, 60,000-79,999, ≥80,000, or missing/unknown), and Charlson comorbidity score (0, 1, ≥2) .
b All models excluded cases and controls who had a sigmoidoscopy but no colonoscopy during the lookback window of interest. The numbers of cases and controls excluded differed according to model, due to varying estimated durations of the occult invasive phase. and mortality. As previously noted, studies of cancer incidence are less susceptible to important biases: distributional differences between cases and controls in levels of testing over time and by age, and misclassification of test indication. The fact that screening tests are clustered near the time of diagnosis in cases means that, in a mortality study, it is more important to accurately specify the relevant time window (i.e., combined PIDP and OIP), because underestimates of the duration of this time period would result in differential misclassification, with screened controls being more likely than screened cases to be classified as unscreened (6) . Test indication is particularly important in studies of colonoscopy's efficacy, because the vast majority of individuals with CRC receive a diagnostic colonoscopy as part of their work-up. For example, a case-control study by Baxter et al. (2)-in which test indication could not be ascertained-noted an approximately 6-fold increase in the odds of CRC death associated with receipt of colonoscopy when all colonoscopies prior to and including the reference date were considered. There are also practical advantages to incidence studies. Determining receipt of colonoscopy is much more straightforward than determining its indication, so incidence studies can be conducted without resource-intensive medical record abstraction to determine exposure status, making administrative claims a good source of study data.
Finally, considering cancer incidence as the outcome allows for the determination of the impact of colonoscopy performed for any reason on the subsequent incidence of cancer. For example, diagnostic colonoscopies conducted due to nonspecific gastrointestinal symptoms (e.g., constipation, abdominal pain) might ultimately prevent the future incidence of CRC if they lead to the diagnosis and removal of adenomas or sessile serrated polyps; as such, inclusion of these types of exams appropriately credits them for their protective benefit. It is important to acknowledge, however, that this broader exposure definitionthat considers colonoscopies performed for any reason-answers a question different from examining the preventive impact of screening per se on cancer incidence; it is possible that the magnitude of the association might differ for screening versus diagnostic colonoscopy. For example, if colonoscopies performed for diagnostic indications are more likely to identify a precancerous polyp, they might have a relatively greater impact in preventing future CRC incidence. While polyps tend to bleed infrequently, it is also possible that diagnostic colonoscopies might be more likely to identify larger, more advanced polyps that would be more likely both to bleed and to progress to invasive disease later on.
Despite these advantages, there are limitations to the conduct of case-control studies of screening efficacy in preventing cancer incidence. For example, the present analysis required independent estimations of both the PIDP and the OIP, which theoretically could result in compounded errors, if both time periods are misspecified. The PIDP and the OIP are both variable between individuals and impossible to know precisely in any one individual. Therefore, uncertainty regarding the length of both the PIDP and the OIP can be a source of bias affecting case-control studies of screening to prevent cancer incidence or mortality. However, in this particular instance the estimated odds ratios were robust to different estimates of the PIDP and OIP, which is reassuring. Also, studying the joint impact of both screening and diagnostic exams in preventing cancer incidence requires consideration of other factors that might affect the likelihood of both colonoscopy and CRC. In this analysis, we attempted to address this issue by excluding persons with inflammatory bowel disease and prior CRC, because these individuals are both at higher risk of CRC and more likely to receive colonoscopy. And finally, in the case of SEER-Medicare data, there are inherent limitations based on data availability. For example, while information about family history of CRC is theoretically available based on administrative codes, we deemed this information unreliable based on a higher prevalence in controls than in cases, and therefore did not include this variable in our models, likely resulting in some degree of residual confounding. Also, for cancer cases diagnosed in 2003 or later, only 5-7 years of claims data before diagnosis were available. Again, however, this seems less problematic for incidence studies, 0, 1, ≥2) .
b All models excluded cases and controls who had a sigmoidoscopy but no colonoscopy during the lookback window of interest. The numbers of cases and controls excluded differed according to model, due to varying lookback window lengths and estimated durations of the occult invasive phase.
given that we observed fairly consistent odds-ratio estimates even as we varied the PIDP and OIP estimates. Last, the nature of Medicare coverage necessitated that we consider only colonoscopies occurring at age 65 years or older. Colonoscopies occurring at younger ages are not available in SEER-Medicare, yet they had a potentially strong impact on the subsequent incidence of CRC. However, colonoscopy screening is recommended every 10 years from age 50 through 75 years, and colonoscopy surveillance is recommended more frequently in those with prior colorectal polyps, with no recommended stopping age (15) ; therefore, at least 1 colonoscopy would be recommended between ages 65 and 85 years in our study population. Nonetheless, our estimated odds ratios could be attenuated if, due to limited length of the lookback window, some individuals were misclassified as unexposed despite having had a colonoscopy prior to age 65 years.
In summary, administrative claims data when linked to cancer outcomes (such as SEER-Medicare data) can provide an efficient data source for examining the efficacy of cancer screening tests that have the ability to prevent cancer incidence. In contrast, because the validity of case-control studies of screening to prevent cancer mortality relies on accurate classification of test indication, use of administrative data must be coupled with strategies for obtaining this information. For example, for large administrative data sets, it might be possible to assign test indication through the use of electronic algorithms that examine patterns of medical diagnoses and procedures occurring around the time of the exam (16) (17) (18) (19) . However, it is important to ensure that these algorithms are well-validated in order to minimize any bias from misclassification of test indication for casecontrol studies of screening in relation to cancer mortality.
